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PURPOSE: In the United States, adjuvant radiation therapy is
currently recommended for most patients with rectal can-
cer. We conducted this population-based study to evaluate
the rate of radiation therapy and the factors affecting its
delivery. METHODS: We used the Surveillance Epidemiol-
ogy and End Results database to assess treatment of patients
with nonmetastatic rectal cancer diagnosed over a 25-year
period (1976 through 2000). We evaluated the rate of ra-
diation therapy use and its timing (preoperative vs. postop-
erative) and the influence of factors such as tumor stage and
grade; patient gender and race; and geographic location.
RESULTS: In this 25-year period, 45,627 patients met our
selection criteria. The rate of radiation therapy use in-
creased dramatically over time: from 17 percent of ad-
vanced-stage patients in 1976 to 65 percent in 2000 (P <
0.0001). Until 1996, the increase was due almost entirely to
postoperative radiation therapy. Since 1996, the rate of pre-
operative radiation therapy use has increased (P < 0.0001)
and the rate of postoperative radiation therapy use has be-
gun to decline. We found, after controlling for the year of
diagnosis, that female patients, African Americans, older pa-
tients, and patients with low-grade lesions were less likely
to undergo radiation therapy (P < 0.0001). Geographic lo-
cation was also an important predictor of radiation therapy
use. CONCLUSIONS: The use of radiation therapy for pa-
tients with rectal cancer has dramatically increased over the
25-year period studied, with a recent shift to the use of
preoperative radiation therapy; however, in 2000, over 30
percent of patients with advanced-stage nonmetastatic rec-
tal cancer did not undergo radiation therapy. Given the
variation in radiation therapy use that we found to be due to
demographic factors, access to adjuvant radiation therapy
can be improved. [Key words: Rectal cancer; Adjuvant ra-
diation; Patterns of care; Staging; Preoperative radiation]
R ectal cancer, a common cancer, is associatedwith significant morbidity and mortality. In 2004,
almost 41,000 Americans will develop rectal cancer.1
The traditional treatment of this disease has relied on
radical resection. Unfortunately, in the past, such pa-
tients experienced significant rates of local recur-
rence. Reported rates of local recurrence were as high
as 30 percent,2 with a median local recurrence rate of
18.5 percent.3 Local recurrence is a multifactorial
problem and is affected by tumor, patient, and treat-
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ment factors. The high rates of recurrence led to ef-
forts to improve local tumor control. Standardization
of the surgical approach, including meticulous dissec-
tion of the mesorectum (total mesorectal excision),
significantly reduced local recurrence after radical ex-
cision of rectal cancer in many centers.4,5 Nonethe-
less, local recurrence remains a problem.
In 1990, the National Institutes of Health (NIH)
Consensus Conference established adjuvant postop-
erative radiation therapy, along with chemotherapy,
as the standard of care for achieving regional control
of Stage II and III rectal cancer after surgical resection
in the United States.6 Numerous studies have substan-
tiated the benefits of adjuvant radiation therapy for
preventing local recurrence in patients with rectal
cancer.7–10 However, we do not know the rate of ra-
diation therapy use in patients with rectal cancer, or
the timing of radiation therapy (preoperative vs. post-
operative). Most previous assessments of the rate of
radiation therapy use have included only individuals
age 65 and older,11,12 have included only small num-
bers of patients,13 or have not been population
based14; only one such study evaluated trends over
time.14
The aim of our population-based study was to
evaluate U.S. trends in adjuvant radiation therapy use
over a 25-year period, timing (preoperative vs. post-




We used data from the Surveillance Epidemiology
and End Results (SEER) cancer registry to conduct this
study. SEER, a population-based registry sponsored
by the National Cancer Institute, collects information
on cancer incidence and survival from 11 population-
based cancer registries and 3 supplemental registries;
these 14 registries include approximately 14 percent
of the U.S. population.12 Two of the 11 registries were
added in 1992. The information collected by SEER
includes patient characteristics, county of residence,
primary tumor site, tumor grade, and stage at diagno-
sis. Although formal American Joint Committee on
Cancer (AJCC) staging information has only been
available in SEER since 1988, SEER has coded disease
as localized, regional, or metastatic since its inception.
Regional disease is described as having direct exten-
sion into adjacent organs or involvement of regional
lymph nodes, and thus would include some AJCC
Stage II lesions (T4N0) and AJCC Stage III lesions.
Other information collected by SEER includes first
course of treatment (through completion of the initial
treatment plan, including treatment within the first
year after diagnosis or until there is evidence, within
the first year, either of disease progression or of treat-
ment failure), radiation sequence with respect to sur-
gery, and follow-up for vital status.12 SEER does not
collect information regarding administration of che-
motherapy.
Patients
We included patients age 18 or older who were
diagnosed with adenocarcinoma of the rectum from
January 1976 through December 2000. Excluded from
our study were patients who had in situ or metastatic
disease, patients with malignancies other than adeno-
carcinoma, and patients who did not undergo some
form of surgical therapy.
Analysis
We determined the overall rate of radiation, preop-
erative radiation, and postoperative radiation. We
evaluated the effect of demographic, surgical, and tu-
mor factors on radiation and determined time trends.
We compared means using the Wilcoxon rank-sum
test and proportions using the chi-squared test. We
used the Cochran-Armitage trend test on one degree
of freedom to determine whether rates had changed
over time. We used logistic regression to test the as-
sociations between radiation and age, race, gender,
year of diagnosis, tumor grade, tumor stage, surgical
treatment, and geographic location by registry. We
limited the logistic regression to patients diagnosed
from 1988 through 2000, such that only patients with
available AJCC staging were included. Our analysis
was limited to patients for whom radiation is routinely
recommended (AJCC Stage II and III patients).
Our study used preexisting data with no personal
identifiers, and was thus exempt from review by the
University of Minnesota’s Institutional Review Board.
RESULTS
A total of 45,627 patients in our 25-year study pe-
riod were diagnosed with rectal cancer and met our
selection criteria. In 99 percent of these patients (n =
45,000), radiation status could be determined. Of
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these patients 14,571 (32 percent) underwent radia-
tion therapy (Table 1). Patients who underwent radia-
tion therapy tended to be younger (median age, 65)
than those who did not undergo radiation therapy
(median age, 70) (P < 0.0001). They were more likely
to be male (61 percent male, radiation therapy, vs. 55
percent male, no radiation therapy; P < 0.0001). Pa-
tients who underwent radiation therapy were also
more likely to have regional spread (64 percent) than
those who did not undergo radiation therapy (29 per-
cent) (P < 0.0001). In addition, patients who under-
went radiation therapy were more likely to have also
undergone radical excision as part of treatment (90
percent) than those who did not undergo radiation
therapy (73 percent) (P < 0.0001). Of note, detailed
surgical information has only been available in SEER
since 1983. Before adjustment for other factors, Afri-
can Americans were slightly more likely to receive
radiation (35 percent) than non–African Americans
(32 percent) (P < 0.0003). However African Americans
were also more likely to have regional disease (47
percent of those with known stage) than non–African
Americans (42 percent of those with known stage)
(P < 0.00001).
The frequency of radiation therapy use for patients
with rectal cancer substantially increased over our
study time period: 12 percent of such patients under-
went radiation therapy in 1976 vs. 42 percent in 2000
(P < 0.0001; Fig. 1). For patients with regional spread,
the increase was even more dramatic: from 17 percent
in 1976 to 65 percent in 2000. Of those with regional
spread who underwent radical excision, 41 percent
underwent radiation therapy in 1983 vs. 65 percent in
2000 (P < 0.0001; Fig. 1). No dramatic change in the
rate of increase of radiation therapy use has occurred
in the years following 1990 (the year of the NIH Con-
sensus Conference statement recommending adjuvant
radiation therapy for AJCC Stage II and III rectal can-
cer). For AJCC Stage II patients, the rate of radiation
therapy use in 2000 was 59 percent; for Stage III pa-
tients it was 68 percent.
The increase in radiation therapy use was due al-
most entirely to postoperative radiation therapy use
until 1996. Since that time, the rate of preoperative
radiation therapy use has significantly increased (P <
0.0001) and the rate of postoperative radiation has
actually begun to decline (Fig. 2). Of note, we found
significant staging differences for patients who under-
went preoperative radiation vs. those who underwent
postoperative radiation. Patients who underwent pre-
Table 1.




(N = 14,571 (32%))
No Radiation Therapy Usea
(N = 30,429 (68%))
Age in years (median) 68 65 70
Male:female ratio (%) 57:43 61:39 55:45
Raceb
Non–African American 42,965 (94%) 13,670 (94%) 28,728 (95%)
African American 2,545 (6%) 888 (6%) 1,599 (5%)
SEER stage
Localized spread 24,992 (54.7%) 4,267 (29%) 20,528 (67%)
Regional spread 18,559 (40.6%) 9,351 (64%) 8,809 (29%)
Unknown 2,076 (4.5%) 953 (7%) 1,092 (4%)
Year of diagnosis
1976–1980 7,342 1,093 (15%) 6,181 (85%)
1981–1985 8,188 2,054 (25%) 6,038 (75%)
1986–1990 8,177 2,708 (33%) 5,377 (67%)
1991–1995 9,990 3,747 (38%) 6,057 (62%)
1996–2000 11,930 4,969 (42%) 6,776 (58%)
Grade
Well differentiated 5,706 (13%) 1,166 (8%) 4,480 (15%)
Moderately differentiated 25,982 (57%) 9,095 (62%) 16,506 (54%)
Poorly differentiated 5,980 (13%) 2,776 (19%) 3,094 (10%)
Unknown 7,959 (17%) 1,534 (11%) 6,349 (21%)
Radical resection (%)c 79% 90% 73%
SEER = Surveillance Epidemiology and End Results.
aRadiation status unknown in 627 (1%) patients.
bRace information missing for 117 patients (<1%).
cSurgery information available since 1983.
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operative (vs. postoperative) radiation were more
likely to be missing stage information (18 percent vs.
2 percent; P < 0.0001); they were also more likely to
have localized disease (38 percent vs. 26 percent; P <
0.0001). Conversely, patients who underwent preop-
erative (vs. postoperative) radiation were less likely to
have regional spread (44 percent vs. 72 percent; P <
0.0001).
In our multivariate models, controlling for the year
of diagnosis and geographic location by registry, we
found that male gender and younger age were pre-
dictors of radiation therapy use (P < 0.0001) (Table 2).
African Americans were less likely to undergo radia-
tion therapy (P < 0.003) than patients of other races.
Patients with poorly differentiated rectal cancer and
those with AJCC Stage III rectal cancer were signifi-
cantly more likely to undergo radiation therapy than
those with well-differentiated or moderately differen-
tiated rectal cancer or with AJCC Stage II cancer (P <
0.0001). In all our multivariate models, the year of
diagnosis and geographic location by registry re-
mained important predictors of radiation therapy (P <
0.0001).
DISCUSSION
Our study demonstrates a gradual but persistent
increase in adjuvant radiation therapy use for patients
with rectal cancer over a 25-year period: from 17 per-
cent in 1976 to 65 percent in 2000 for patients with
regional spread. Interestingly, despite the NIH Con-
sensus Conference recommendations in 1990, the rate
of radiation therapy use did not dramatically rise after
that recommendation. Thus the increase was not in
direct response to it. In terms of AJCC staging (avail-
able in SEER only since 1988), we found that the rate
of radiation therapy use in 2000 was 59 percent for
AJCC Stage II patients and 68 percent for AJCC Stage
III patients. Although most patients underwent appro-
priate adjuvant radiation therapy, substantial numbers
of patients who might benefit from therapy did not
receive it—perhaps more than 7,000 patients in the
United States per year (extrapolating from our data to
the U.S. population). In many cases, patients may not
have undergone radiation therapy because of appro-
priate medical considerations (e.g., extreme medical
comorbidity) or because of their own preference.
However, given the variations in adjuvant radiation
therapy use that we identified with regard to age,
race, gender, and geographic location, and given the
considerable change in the rate over time, it is likely
that other modifiable factors—such as the underlying
practice patterns of individual surgeons or institu-
tions—played an important role.
The overall rate of adjuvant radiation therapy use
that we found in 2000 for AJCC Stage II (59 percent)
and Stage III patients (68 percent) appears to be
higher than the rate found in other population-based
studies. Two previous studies used SEER data linked
to Medicare data to examine the rate of adjuvant ra-
diation and chemotherapy use in individuals age 65
and older from 1992 through 1996. One of these stud-
Figure 1. Proportion of all patients diagnosed with rectal
cancer who underwent radiation therapy over time. Solid
line = proportion of patients undergoing radiation therapy,
all patients; dashed line = proportion of patients undergo-
ing radiation therapy, of those with regional spread who
underwent radical resection. Information on extent of sur-
gical resection was available only from 1983.
Figure 2. Proportion of patients with regional spread who
underwent radiation therapy over time. Solid line = pro-
portion of patients with regional spread who did not un-
dergo radiation therapy; dashed line = proportion of pa-
tients with regional spread who underwent preoperative
radiation therapy; gray line = proportion of patients with
regional spread who underwent postoperative radiation
therapy.
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ies found a rate of radiation use of 51 percent12; the
other, 57 percent.11 Both focused on AJCC Stage II
and III patients. But given the influence of older age
on radiation therapy use that numerous studies11–13
(including ours) have noted, those two studies of in-
dividuals age 65 and older do not apply to younger
patients. In a similar study evaluating 534 adult pa-
tients who developed rectal cancer in 1996 and 1997
while residing in California Cancer Registry regions,
the unadjusted rates of adjuvant radiation varied from
82 percent in patients younger than 55 years old to 14
percent in patients at least 85 years of age. It is note-
worthy that none of the population-based studies
evaluated trends over time. None of the previous
studies evaluated trends in preoperative delivery of
adjuvant radiation.
The National Cancer Data Base (NCDB)14 reported
trends in rectal cancer treatment over time, comparing
treatment in 1985–86, 1989–90, and 1994–95. A much
smaller change in the use of adjuvant radiation was
seen in this NCDB report: adjuvant radiation therapy
use increased from 54 percent in AJCC Stage III pa-
tients in the first years studied to 61 percent in the
final years studied. The NCDB study was not popula-
tion based, and its findings in 1994–95 may not be
directly comparable to the earlier time periods; the
proportion of rectal cancer patients in the United
States included in the NCDB increased from 24 per-
cent of all patients in 1985–86 to 53 percent in 1994–
95. Hospitals reporting data in the first years of the
NCDB study likely had substantially different treat-
ment practices, compared with hospitals recruited to
the NCDB in subsequent years or compared with all
hospitals in the United States. In addition, the NCDB
study did not look at trends in preoperative radiation
therapy.
Consistent with growing evidence of the effective-
ness and superiority of preoperative radiation,7–9,15,16
our study demonstrates a substantial increase in its
use since 1996. In fact, although the overall rate of
any adjuvant radiation has continued to increase,
since 1996 the rate of postoperative radiation has ac-
tually declined. In our study, we noted important dif-
ferences in staging between patients who underwent
preoperative radiation. Patients who underwent pre-
operative vs. postoperative radiation were more likely
to be missing staging information or to have early-
stage disease. We are not able to determine whether
those differences were caused by a complete patho-
logic tumor response (which occurs in 10 percent to
Table 2.






>70 years 1 Reference group
<65 to 70 years 3.03 2.76–3.33
60 years 4.95 4.48–5.46
Genderb
Male 1 Reference group
Female 0.81 0.75–0.88
Racec
Non–African American 1 Reference group
African American 0.77 0.65–0.92
AJCC tumor stageb
AJCC II 1 Reference group
AJCC III 1.76 1.62–1.90
Gradeb
Poorly differentiated 1 Reference group
Moderately differentiated 0.79 0.72–0.88
Well differentiated 0.71 0.60–0.85
Type of surgeryd
Local 1 Reference group
Radical 1.34 1.01–1.79
aIncludes patients since 1988, adjusted for geographic location by registry and by year of diagnosis. AJCC = American
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20 percent of rectal cancer patients who undergo pre-
operative chemoradiation therapy)17–20; by down-
staging because of partial tumor response after radia-
tion; by uncertainty on the part of the person doing
the staging as to how to interpret AJCC rules after
preoperative therapy; by inadequate nodal evalua-
tion; or by other factors. However, given the increas-
ing rate of preoperative radiation therapy use, re-
searchers using the SEER database in the future must
carefully consider its influence on stage distribution in
SEER. In fact, because of the effect of preoperative
radiation on staging and the increasing frequency in
the use of preoperative radiation, stage-specific re-
search using SEER may be difficult or impossible.
Our population-based study included large num-
bers of patients. Yet only limited information on pa-
tient and tumor characteristics is available from SEER.
Such characteristics, of course, may affect treatment
decisions, but we could not control for them in our
study. Of note, SEER does not include information on
administration of chemotherapy, so we could not
evaluate the use of adjuvant chemotherapy in combi-
nation with radiation. Because the formal AJCC stage
is only available in SEER as of 1988, we could not
evaluate radiation trends with regard to AJCC stage for
our entire study period. Still, in the final year of our
study the rates of adjuvant radiation use were similar
in patients with regional spread per SEER (65 percent)
and those with AJCC Stage III disease (68 percent).
This finding, we believe, justifies our use of SEER
staging to evaluate trends.
Despite these limitations, our study demonstrated a
dramatic increase in adjuvant radiation use for rectal
cancer patients over time and also demonstrated a
recent shift from postoperative to preoperative adju-
vant radiation therapy. However, even in the final
year of our study, we noted that significant numbers
of patients who might have benefited from radiation
did not undergo it. Given the variations in adjuvant
radiation therapy use by patient age at diagnosis, gen-
der, race, and geographic location identified in our
study and in others,11–13,21 access to this beneficial
and recommended therapy can still be improved.
Continued study of treatment trends and of factors
influencing them is needed.
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